Search
Displaying 471–480 of 762 for “retinitis clinical trial”
-
A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies
In the PressAN EMERGING, vision-restoring gene therapy for a devastating retinal disease is poised for Food and Drug Administration (FDA) approval. If it gets the regulatory nod, it will be the first gene therapy to receive FDA approval for the eye or an inherited condition.
-
Investing in Cures Summit 2021
The 2021 Investing in Cures Summit (ICS) convenes key stakeholders of the Foundation Fighting Blindness and RD Fund to learn from the world’s leading industry, clinical and retinal science innovators poised to take emerging therapies across the finish line.
-
Funded Grants and Awards for Fiscal Year 2019 (July 1, 2018-June 30, 2019)
-
Foundation News
Uni-Rare Study will improve clinical understanding of more IRDs and boost development of potential therapies.
-
BioBonds in New York Times: Ask Congress to Support Biomedical Research for Treatments and Cures
In the PressKaren Petrou invented a new funding model for curing blindness. Proposed legislation aims to apply it to medical research more generally.
-
Foundation News
Course Title: Clinical Trials of Emerging Therapies for Retinal Degeneration Patients: Hope and Opportunities
-
Individual Investigator Research Award (IIRA)
Individual Investigator Research Awards are designed to concentrate research in areas with the greatest potential to move toward treatments and cures for the inherited orphan retinal degenerative diseases and dry age-related macular degeneration. This award provides approximately $100,000 per year up to three (3) years. These opportunities seek candidates that hold a Ph.D., M.D., M.D./Ph.D., D.M.D., D.V.M., D.O., O.D., or equivalent degree and have a faculty position or equivalent at a domestic or foreign: non-profit organization, or public or private institution, such as a university, college, medical school, hospital, research institute, or laboratory. Individuals from underrepresented racial, ethnic and gender groups, as well as individuals with disabilities, are always encouraged to apply.
-
Foundation News
Collaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
In the Press
Funds to support advancement of two clinical trials through proof of concept: NPI-001 for retinitis pigmentosa in Usher syndrome and NPI-002 to slow cataract progression.
